Vilnius University Hospital Santaros Klinikos
Vilnius, 08661, Lithuania
Location status: Recruiting
Location contact
Matas Jakubauskas, PhD
CONTACT
Tomas Poskus, PhD
CONTACT
NCT Number: NCT06502704
Currently colorectal cancer pathogenesis is mainly explained by the adenoma-carcinoma sequence theory that was proposed more than half a century ago. It mainly focuses on the explanation of genetic mutations that develop throughout the disease course. However, several studies argue that there are also noticeable bile acid metabolism changes and microbiome composition changes within in colorectal cancer patients. However, carcinoma is the final step in the sequence, and prior steps are noticeably less well studied. Thus, the investigators hypothesize, that changes within microbiome and the changes in the urine, serum and gut bile acid composition further leads to the development of colorectal adenoma and subsequent invasive carcinoma.
Adult participants (15 per group) referred for colonoscopy and histologically diagnosed with small (<1cm) adenomas, large (>1cm) adenomas, invasive CRC will be included in the study, as well as 15 healthy controls. Fecal samples will be collected from all participants before bowel preparation. Additionally, urine and serum samples will be collected. Participants will undergo polypectomy, endoscopic mucosal resections, depending on the location, size and histology of the polyp found. During colonoscopy the mucosal biopsy specimens from the lesion and from the healthy bowel -terminal ileum, and colon will be obtained using sterile biopsy forceps. The collected samples will be stored for bile acid and microbiome analysis and for possible further pathology and genetic testing. Healthy participants without visible colorectum pathology during colonoscopy will undergo colon and terminal ileum mucosal sampling.
The investigators plan to evaluate the correlation between the urine and gut microbiome changes and bile acid composition and concentration in adenoma-carcinoma sequence and possibly determine novel bile acids. In addition, fecal, urine and tissue samples will be explored for gut microbiota and bile acid composition changes in healthy and along the adenoma-carcinoma sequence, with the possibility to propose a diagnostic test.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Vilnius, 08661, Lithuania
Location status: Recruiting
Matas Jakubauskas, PhD
CONTACT
Tomas Poskus, PhD
CONTACT
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Through study completion, an average of 2 years
Microbiome and bile acid composition changes will be detected and correlated with progression of the dysplastic changes within the epithelium of the large bowel.
Time frame: Through study completion, an average of 2 years
Compare bile acid composition of healthy controls to patients with early and advanced adenomas and colorectal cancer, novel bile acid identification that could play a role in the adenoma-carcinoma sequence and identify the diagnostic potential of bile acid composition patterns
Time frame: Through study completion, an average of 2 years
Determine the bile acid composition in urine, stool and serum of healthy controls
Contact information is provided by the study sponsor or research team.
Matas Jakubauskas, PhD
CONTACT
Tomas Poskus, PhD
CONTACT
Vilnius University
Other
Bile Acids and Microbiome - Possible Novel Progression Factors and Diagnostic Indicators in Early Colorectal Carcinogenesis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05612347
Colonic Diseases, Colorectal Adenoma
Birmingham, Alabama, United States
View Trial DetailsNCT06342440
Colonic Diseases, Colonic Neoplasms
Monrovia, California, United States
View Trial DetailsNCT05988645
Colonic Diseases, Colorectal Adenocarcinoma
Barcelona, Spain
View Trial DetailsNCT05636085
Colonic Diseases, Colorectal Adenoma
View Trial Details